NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

por van den Heuvel, Michel M, Verheij, Marcel, Boshuizen, Rogier, Belderbos, José, Dingemans, Anne-Marie C, De Ruysscher, Dirk, Laurent, Julien, Tighe, Robert, Haanen, John, Quaratino, Sonia
Publicado 2015

Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score

por Clive, Amelia O, Kahan, Brennan C, Hooper, Clare E, Bhatnagar, Rahul, Morley, Anna J, Zahan-Evans, Natalie, Bintcliffe, Oliver J, Boshuizen, Rogier C, Fysh, Edward T H, Tobin, Claire L, Medford, Andrew R L, Harvey, John E, van den Heuvel, Michel M, Lee, Y C Gary, Maskell, Nick A
Publicado 2014

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer

por ter Heine, Rob, van den Heuvel, Michel M., Piet, Berber, Deenen, Maarten J., van der Wekken, Anthonie J., Hendriks, Lizza E. L., Croes, Sander, van Geel, Robin M. J. M., Jansman, Frank G. A., Boshuizen, Rogier C., Franssen, Eric J. F., Smit, Arthur A. J., Dumoulin, Daphne W., Oude Munnink, Thijs H., Smit, Egbert F., Derijks, Hieronymus J., van der Leest, Cor H., Hendrikx, Jeroen J. M. A., Moes, Dirk J. A. R., de Rouw, Nikki
Publicado 2023